Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

GSK1360707F

From Wikipedia, the free encyclopedia
Chemical compound
The topic of this articlemay not meet Wikipedia'sgeneral notability guideline. Please help to demonstrate the notability of the topic by citingreliable secondary sources that areindependent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to bemerged,redirected, ordeleted.
Find sources: "GSK1360707F" – news ·newspapers ·books ·scholar ·JSTOR
(August 2014) (Learn how and when to remove this message)
Pharmaceutical compound
GSK1360707F
Identifiers
  • (1R,6S)-1-(3,4-Dichlorophenyl)-6-(methoxymethyl)-4-azabicyclo[4.1.0]heptane
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC14H17Cl2NO
Molar mass286.20 g·mol−1
3D model (JSmol)
  • COC[C@@]12C[C@@]1(CCNC2)c3ccc(c(c3)Cl)Cl
  • InChI=1S/C14H17Cl2NO/c1-18-9-13-7-14(13,4-5-17-8-13)10-2-3-11(15)12(16)6-10/h2-3,6,17H,4-5,7-9H2,1H3/t13-,14-/m0/s1
  • Key:ICXJGCSEMJXNQF-KBPBESRZSA-N
  (verify)

GSK1360707F is a potent and selectivetriple reuptake inhibitor.[1] It is chemically related toamitifadine andNS-2359 (GSK-372,475). Until recently,[when?] it was under development for the treatment ofmajor depressive disorder; its development was put on hold for strategic reasons.[citation needed]

Synthesis

[edit]
Synthesis of GSK1360707F[2]
  1. BOCProtecting group.
  2. Enolization and trapping withtriflate group (cfComins' reagent).
  3. Suzuki reaction
  4. Reduction (only 1 mol eq. LAH because N-BOC can be reduced to N-Me)
  5. Trifluoroacetic acid (TFA) removal of protecting group.
  6. Simmons–Smith reaction cyclopropanation.
  7. Williamson ether synthesis (c.f. NS patents & paxil).

Transporter occupancy

[edit]

GSK1360707F has recently (2013) been tested onbaboons (Papio anubis) & humans for transporter occupancy usingPET.[3]

See also

[edit]

References

[edit]
  1. ^Micheli F, Cavanni P, Andreotti D, Arban R, Benedetti R, Bertani B, et al. (July 2010). "6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor".Journal of Medicinal Chemistry.53 (13):4989–5001.doi:10.1021/jm100481d.PMID 20527970.
  2. ^WO 2008031772, Bertani, Barbara; Di Fabio, Romano & Micheli, Fabrizio et al., "Azabicyclic compounds as inhibitors of monoamines reuptake", published 2008-03-20, assigned toGlaxo Group Ltd. 
  3. ^Comley RA, Salinas CA, Slifstein M, Petrone M, Marzano C, Bennacef I, et al. (August 2013). "Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography".The Journal of Pharmacology and Experimental Therapeutics.346 (2):311–7.doi:10.1124/jpet.112.202895.PMID 23685546.S2CID 2964324.
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Retrieved from "https://en.wikipedia.org/w/index.php?title=GSK1360707F&oldid=1120162505"
Category:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp